Peptides / Gut and digestion

Synthetic analog · 33 amino acids · 3,752.1 Da

Teduglutide

ApprovedNot banned in sport

Teduglutide (Gattex, Revestive) is a GLP-2 analog approved in the US and EU for short bowel syndrome in people who depend on IV nutrition. Studies in people tested it on hospital outcomes, IV nutrition needs and quality of life, and tracked side effects. PepBank shows 239 results on teduglutide from 36 studies in people, and 123 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as Gattex, Revestive

33 amino acids, from first to last0 changed amino acids

Evidence level: Large trials in people239 of 362 results come from studies in people, including randomized trials.

Results in people

239

66% of 362 results

Results in animals

27% of 362 results

Results in lab cells

7% of 362 results

From computer models

0% of 362 results

Overview

Teduglutide at a glance

What it is	Synthetic analog, 33 amino acids
Approval	Approved in the US and EU (Gattex)
In sport	Not listed as banned by WADA
Studies	54 studies with results. All of them gave teduglutide, with 362 results. 239 in people98 in animals25 in lab cells
Best study in people	Randomized controlled trial with 83 people (2011)
Clinical trials	46 registered: 4 active or planned, 20 with posted results
Community use	Adults and pediatric patients 1 year of age and older with short bowel syndrome who depend on parenteral support.

The science

What is teduglutide?

Teduglutide is a 33-residue GLP-2 analog.

Amino acids in one chain

The history of teduglutide

2004
The oldest paper on teduglutide in PepBank is from 2004.
2004May
A registered trial of teduglutide started (NCT00081458).

Teduglutide structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 33 amino acidsFrom the first amino acid to the last

H1G−DGS5FS−D−EM10NTIL−D15NLAA+R20−DFINW25LIQT+K30IT−D

Darker means more water-repelling+ and − show charge in the body

Structure

Teduglutide is a synthetic analog of 33 amino acids, with no ring, no changed amino acids.

Formula

C₁₆₄H₂₅₂N₄₄O₅₅S

Molecular weight

3,752.1 g/mol

CAS number

197922-42-2

Target

Glucagon-like peptide 2 receptor (gene GLP2R): agonistEvidence: Official prescribing information, mechanism of action

Development

Highest phase: past the trial stage (see status).

Identifiers

PubChem 16139605, ChEMBL CHEMBL2104987, UNII 7M19191IKG, DrugBank DB08900

Full sequence, SMILES and InChIKey

InChIKey
CILIXQOJUNDIDU-ASQIGDHWSA-N

SMILES
CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC5=CN=CN5)N

See charge, composition and 3D structure on the Scientific page

The evidence

What teduglutide studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Large trials in people239 of 362 results come from studies in people, including randomized trials.

Survival and serious illness

87 results · 87 in people

In patients with short bowel syndrome, teduglutide 0.05 mg/kg/day improved graded response versus placebo. Gut, 2011

Top results

In patients with short bowel syndrome, teduglutide 0.05 mg/kg/day improved graded response versus placebo. (Gut, 2011)
In healthy subjects, no deaths occurred during the study, including among teduglutide recipients. (BMC gastroenterology, 2014)
In the overall SBS-IF population, the response-rate difference favored teduglutide over placebo. (Therapeutics and clinical risk management, 2018)

Stomach and gut

93 results · 36 in people · 57 animal

In SBS-IF patients, teduglutide produced more parenteral support volume responders than placebo. Gastroenterology, 2012

Top results

In SBS-IF patients, teduglutide produced more parenteral support volume responders than placebo. (Gastroenterology, 2012)
Five of six adults had the defined fistula-volume response with teduglutide, but not with standard care. (Clinical nutrition ESPEN, 2022)
In healthy subjects, acetaminophen exposure to the last measurement did not differ significantly between teduglutide and placebo. (BMC gastroenterology, 2014)

Daily life and fitness

13 results · 13 in people

In SBS-IF patients, teduglutide did not significantly improve the total quality-of-life score compared with placebo. Clinical nutrition, 2013

Top results

In SBS-IF patients, teduglutide did not significantly improve the total quality-of-life score compared with placebo. (Clinical nutrition, 2013)
In adults with SBS, teduglutide numerically improved quality-of-life scores versus placebo, without statistical significance. (JPEN. Journal of parenteral and enteral nutrition, 2020)
Children with SBS-IF receiving teduglutide had a mean quality-of-life score of 75.0. (Journal of pediatric gastroenterology and nutrition, 2026)

Overall treatment results

5 results · 5 in people

In patients with Crohn's disease, clinical response rates were numerically higher with teduglutide than placebo. Inflammatory bowel diseases, 2010

Top results

In patients with Crohn's disease, clinical response rates were numerically higher with teduglutide than placebo. (Inflammatory bowel diseases, 2010)
In Crohn's disease, response was 44% with the highest teduglutide dose versus 32% with placebo. (Inflammatory bowel diseases, 2010)
In patients with Crohn's disease, remission rates were numerically higher with teduglutide than placebo. (Inflammatory bowel diseases, 2010)

Heart and blood vessels

4 results · 4 in people

In healthy volunteers, QTcF curves after both teduglutide doses were almost identical to placebo curves. Clinical pharmacology in drug development, 2012

Top results

In healthy volunteers, QTcF curves after both teduglutide doses were almost identical to placebo curves. (Clinical pharmacology in drug development, 2012)
In healthy men, teduglutide rapidly increased blood flow to the intestine. (Diabetes, obesity & metabolism, 2019)
In healthy volunteers, the upper confidence bound for QTcF change after teduglutide 5 mg was 3.0 ms. (Clinical pharmacology in drug development, 2012)

Liver

11 results · 3 in people · 8 animal

In adults with SBS-IF, teduglutide reduced AST more than placebo at week 24. Nutrition in clinical practice, 2024

Top results

In adults with SBS-IF, teduglutide reduced AST more than placebo at week 24. (Nutrition in clinical practice, 2024)
In adults with SBS-IF, teduglutide reduced ALT more than placebo at week 24. (Nutrition in clinical practice, 2024)
In adults with SBS-IF, teduglutide reduced bilirubin more than placebo at week 24. (Nutrition in clinical practice, 2024)

Teduglutide has 256 linked papers. PepBank read up to 120 of the most-cited studies that gave it to people, up to 20 other studies, and the main trials.

All 54 teduglutide studies by area Open the Scientific page

Key teduglutide studies

Studies in people come first, then studies in animals and in the lab.

People
Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome
Jeppesen et al. 2011 · Gut · 83 people · cited by 323
8 results
People
A randomized, double-blind, placebo-controlled, multiple-dose, parallel-group clinical trial to assess the effects of teduglutide on gastric emptying of liquids in healthy subjects
Berg et al. 2014 · BMC gastroenterology · 36 people · cited by 13
7 results
People
Teduglutide for the treatment of low-output enterocutaneous fistula - A pilot randomized controlled study
Yeh et al. 2022 · Clinical nutrition ESPEN · 6 people · cited by 4
4 results
People
Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease
Buchman et al. 2010 · Inflammatory bowel diseases · cited by 109
7 results
People
Malnutrition enteropathy in Zambian and Zimbabwean children with severe acute malnutrition: A multi-arm randomized phase II trial
Chandwe et al. 2024 · Nature communications · cited by 9
1 result

All 54 Teduglutide studies

Teduglutide clinical trials

ClinicalTrials.gov lists 46 trials of teduglutide. 4 are active or planned, and 20 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)

Phase 3completed88 people

Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects

Phase 3completed86 people

Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome

Phase 3completed84 people

All 27 Teduglutide trials

Status and safety

Is teduglutide approved?

FDA

United States

Approved

An approved medicine contains it.

EMA

European Union

Approved

An approved medicine contains it.

WADA

Sport

Not banned

Not on the 2026 Prohibited List.

Yes. Approved in the US and EU (Gattex). The FDA label for Gattex says: “Adults and pediatric patients 1 year of age and older with short bowel syndrome who depend on parenteral support” Not listed as banned by WADA.

Laws and labels change, so check the regulator for the current status.

Teduglutide side effects and safety

PepBank has 73 safety results from studies of teduglutide. 73 of them come from studies in people.

Safety results from studies (73)

In patients with short bowel syndrome, teduglutide did not change digestive adverse event probability compared with placebo in adjusted analysis. (JPEN. Journal of parenteral and enteral nutrition, 2017)
In patients with short bowel syndrome, serious adverse events were similar with teduglutide and placebo. (Gut, 2011)
In healthy volunteers, QTcF curves after both teduglutide doses were almost identical to placebo curves. (Clinical pharmacology in drug development, 2012)
In patients with Crohn's disease, adverse events did not differ between teduglutide and placebo. (Inflammatory bowel diseases, 2010)
All 89 children receiving teduglutide had adverse events. (JPEN. Journal of parenteral and enteral nutrition, 2021)
In patients with short bowel syndrome, 34% reported abdominal pain during the teduglutide extension study. (Clinical and translational gastroenterology, 2016)
In children with SBS-IF, most adverse events were moderate or severe both in patients who received teduglutide and in the seven who did not. (Journal of pediatric gastroenterology and nutrition, 2024)
In children with SBS-IF, adverse events occurred in 98% with teduglutide versus 100% with standard care. (JPEN. Journal of parenteral and enteral nutrition, 2020)
In patients with short bowel intestinal failure receiving teduglutide, 35% reported headache. (Clinical gastroenterology and hepatology, 2013)
In adults receiving teduglutide, colon polyps occurred in 18% after exposure and 12% at baseline, with different denominators. (Clinical nutrition, 2020)
In healthy subjects, no serious adverse events occurred during the study, including among teduglutide recipients. (BMC gastroenterology, 2014)
In STEPS-3, all teduglutide-treated patients reported at least one adverse event during treatment. (Nutrition in clinical practice, 2018)
In adults with intestinal fistulas, adverse events during teduglutide treatment were uncommon, minor, and usually resolved during treatment. (Clinical nutrition ESPEN, 2022)
In children under 10 kg with short bowel syndrome, all three teduglutide recipients had adverse events, none considered drug-related. (Pediatrics international, 2026)
In SBS-IF patients, adverse events leading to discontinuation had a similar distribution with teduglutide and placebo. (Gastroenterology, 2012)
In children with SBS-IF, all patients, including teduglutide recipients, had adverse events during treatment. Most events were mild or moderate. (The Journal of pediatrics, 2017)
In healthy subjects, teduglutide treatments were safe and well tolerated. (Journal of clinical pharmacology, 2008)
In SBS-IF patients, no intestinal biopsy showed dysplasia after six months in the teduglutide arm with inconsistent dose reporting. (Journal of clinical gastroenterology, 2013)
In adults with SBS-IF receiving teduglutide, adverse events were mostly mild or moderate, as in other groups. (Therapeutic advances in gastroenterology, 2020)
In Japanese adults receiving teduglutide, adverse events matched the underlying illness and known drug reactions. (Surgery today, 2023)
In teduglutide-treated SBS-IF patients, those with over 100 cm of remaining small intestine had more gut adverse events than an unnamed comparison group. (Clinical nutrition, 2013)
In healthy volunteers, the upper confidence bound for QTcF change after teduglutide 5 mg was 3.0 ms. (Clinical pharmacology in drug development, 2012)
In healthy volunteers, the upper confidence bound for QTcF change after teduglutide 20 mg was 4.5 ms. (Clinical pharmacology in drug development, 2012)
Vomiting occurred in 51.7% of children receiving teduglutide. (JPEN. Journal of parenteral and enteral nutrition, 2021)

See every safety result on the Scientific page

Doses studied (40 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
0.05 mg/kg/day	Human	human	subcutaneous	24 weeks	Randomized trial in people · n = 51	Jeppesen 2011
0.10 mg/kg/day	Human	human	subcutaneous	24 weeks	Randomized trial in people · n = 48	Jeppesen 2011
4 mg once daily	Human	human	subcutaneous	10 days	Randomized trial in people · n = 36	Berg 2014
0.05, 0.10, or 0.20 mg/kg daily	Human	human	subcutaneous	8 weeks	Randomized trial in people	Buchman 2010
0.2 mg/kg/d	Human	human	subcutaneous	Not reported	Randomized trial in people	Buchman 2010
0.05 or 0.10 mg/kg/day	Human	human	subcutaneous	24 weeks	Randomized trial in people · n = 168	Micic 2024
0.05 mg/kg/d	Human	human	Not reported	Not reported	Randomized trial in people · n = 136	Fujioka 2017
0.05 mg/kg/day	Human	human	subcutaneous	24 weeks	Randomized trial in people · n = 86	Jeppesen 2013
5 and 20 mg	Human	human	subcutaneous	single injection	Randomized trial in people · n = 72	Hartmann 2012
0.10 and 0.05 mg/kg/day	Human	human	subcutaneous	24 weeks	Randomized trial in people · n = 67	Jeppesen 2011
0.05 mg/kg/day	Human	human	Not reported	24 weeks	Randomized trial in people	Seidner 2015
0.10 mg/kg/day	Human	human	Not reported	24 weeks	Randomized trial in people	Seidner 2015
0.05 mg/kg/d once daily	Human	human	subcutaneous	24 weeks	Trial in people without random groups · n = 86	Jeppesen 2012
5 mg	Human	human	subcutaneous	single injection	Trial in people without random groups · n = 72	Hartmann 2012
20 mg	Human	human	subcutaneous	single injection	Trial in people without random groups · n = 72	Hartmann 2012
0.025 mg/kg once daily	Human	human	Not reported	24 weeks	Trial in people without random groups	Kocoshis 2020
0.05 mg/kg once daily	Human	human	Not reported	24 weeks	Trial in people without random groups	Kocoshis 2020
10 mg single dose	Human	human	subcutaneous	Not reported	Trial in people without random groups	Nave 2013
0.05 mg/kg/day	Human	human	subcutaneous	up to 24 months (NT/TED and PBO/TED) or up to 30 months (TED/TED)	Trial in people without random groups · n = 88	Schwartz 2016
0.025 mg/kg or 0.05 mg/kg once daily (teduglutide groups)	Human	human	Not reported	24 weeks	Trial in people without random groups · n = 59	Kocoshis 2020
0.05 or 0.10 mg/kg/d	Human	human	Not reported	52 weeks	Trial in people without random groups · n = 52	O'Keefe 2013
0.05 mg/kg/day	Human	human	Not reported	24 and 36 months	Trial in people without random groups · n = 50	Armstrong 2020
0.05 mg/kg/day	Human	human	Not reported	Not reported	Trial in people without random groups · n = 18	Nakamura 2023
0.05 mg/kg/day	Human	human	Not reported	Not reported	Trial in people without random groups · n = 14	Seidner 2018
0.05 mg/kg daily	Human	human	subcutaneous	7 days	Trial in people without random groups · n = 8	Iturrino 2016
0.05 mg/kg/day	Human	human	subcutaneous	Mean exposure 48.9 weeks	Trial in people without random groups · n = 3	Masumoto 2026
0.025 mg/kg/d	Human	human	Not reported	12 weeks	Trial in people without random groups	Carter 2017
0.05 mg/kg/d	Human	human	Not reported	12 weeks	Trial in people without random groups	Carter 2017
0.0125 mg/kg/d	Human	human	Not reported	12 weeks	Trial in people without random groups	Carter 2017
0.05 mg/kg/d	Human	human	Not reported	52 weeks	Trial in people without random groups	O'Keefe 2013
0.10 mg/kg/d	Human	human	Not reported	52 weeks	Trial in people without random groups	O'Keefe 2013
0.10 mg/kg/d	Human	human	subcutaneous	Not reported	Trial in people without random groups	Buchman 2010
10, 15, 20, 25, 30, 50, and 80 mg	Human	human	subcutaneous	8 days	Trial in people without random groups	Marier 2008
20 mg	Human	human	subcutaneous	8 days	Trial in people without random groups	Marier 2008
0.10 mg/kg/d	Human	human	Not reported	24 weeks	Trial in people without random groups	Tappenden 2013
0.05 mg/kg/d	Human	human	Not reported	24 weeks	Trial in people without random groups	Tappenden 2013
0.05 or 0.10 mg/kg/day	Human	human	Not reported	24 weeks	Trial in people without random groups	Seidner 2015
0.05 mg/kg/d	Human	human	Not reported	Median 89 weeks among patients achieving autonomy	Observational study · n = 134	Iyer 2017
0.05 mg/kg/dose	Animal	pig	Not reported	Not reported	Study in live animals · n = 16	Pauline 2021
0.2 mg · kg · day	Animal	pig	Not reported	7 days	Study in live animals · n = 15	Thymann 2014

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

The official US label reports prescription use. The regimen below is label information.

Reported routines and cautions

What people use it for

Adults and pediatric patients 1 year of age and older with short bowel syndrome who depend on parenteral support.S1

Reported regimens

Regimens that community sources report for Teduglutide. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Selected US GATTEX standard regimen for adults and pediatric patients 1 year of age and older with short bowel syndrome and parenteral-support dependence. This selection excludes eGFR below 60 mL/min/1.73 m2. The 5 mg kit is not recommended for pediatric patients below 10 kg.Official label dosing of an approved product	subcutaneous injectionThe label excludes intravenous and intramuscular administration. Injection sites alternate between thighs, upper arms, and abdomen.	0.05 mg/kg per dose	once daily	Not stated	Single official US label source.	S1

Cautions

The label warns about neoplastic growth, intestinal or stomal obstruction, biliary and pancreatic disease, and fluid overload. It requires pretreatment testing and ongoing gastrointestinal and laboratory monitoring. Oral-drug absorption may increase. Discontinuation requires fluid and electrolyte monitoring. The full label gives testing schedules and management conditions.S1

Status notes

Revestive has EU authorisation. The EMA overview describes use from 4 months of age, while the page also retains older indication text. This record selects the US GATTEX regimen and does not apply EU age limits to it.S2

Community sources

S1Gattex US prescribing information (opens in a new tab)dailymed.nlm.nih.gov
S2EMA regulatory information (opens in a new tab)ema.europa.eu

Gaps

This record covers one selected US label regimen. It does not establish a separate non-vendor community regimen. No broad community search or exhaustive treatment-study review was performed in this check. The full label contains additional administration and monitoring requirements. The selected regimen does not establish a fixed treatment duration.

Questions and more

Ask a question about teduglutide

The answer links to every study it uses.

What does the evidence say about teduglutide?Is teduglutide tested in people?Compare with Glepaglutide Compare with Linaclotide

Sources

Database: PepBank data for teduglutide (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about teduglutide

Teduglutide

ApprovedNot banned in sport

Also known as Gattex, Revestive

What it is

Synthetic analog, 33 amino acids

Approval

Approved in the US and EU (Gattex)

In sport

Not listed as banned by WADA

Studies

54 studies with results. All of them gave teduglutide, with 362 results.
239 in people98 in animals25 in lab cells

Best study in people

Randomized controlled trial with 83 people (2011)

Clinical trials

46 registered: 4 active or planned, 20 with posted results

Community use

Adults and pediatric patients 1 year of age and older with short bowel syndrome who depend on parenteral support.

Dose as reported

Class

Species

Route

Duration

Design

Source

0.05 mg/kg/day

Human

human

subcutaneous

24 weeks

Randomized trial in people · n = 51

Jeppesen 2011

0.10 mg/kg/day

Human

human

subcutaneous

24 weeks

Randomized trial in people · n = 48

Jeppesen 2011

4 mg once daily

Human

human

subcutaneous

10 days

Randomized trial in people · n = 36

Berg 2014

0.05, 0.10, or 0.20 mg/kg daily

Human

human

subcutaneous

8 weeks

Randomized trial in people

Buchman 2010

0.2 mg/kg/d

Human

human

subcutaneous

Not reported

Randomized trial in people

Buchman 2010

0.05 or 0.10 mg/kg/day

Human

human

subcutaneous

24 weeks

Randomized trial in people · n = 168

Micic 2024

0.05 mg/kg/d

Human

human

Not reported

Randomized trial in people · n = 136

Fujioka 2017

0.05 mg/kg/day

Human

human

subcutaneous

24 weeks

Randomized trial in people · n = 86

Jeppesen 2013

5 and 20 mg

Human

human

subcutaneous

single injection

Randomized trial in people · n = 72

Hartmann 2012

0.10 and 0.05 mg/kg/day

Human

human

subcutaneous

24 weeks

Randomized trial in people · n = 67

Jeppesen 2011

0.05 mg/kg/day

Human

human

Not reported

24 weeks

Randomized trial in people

Seidner 2015

0.10 mg/kg/day

Human

human

Not reported

24 weeks

Randomized trial in people

Seidner 2015

0.05 mg/kg/d once daily

Human

human

subcutaneous

24 weeks

Trial in people without random groups · n = 86

Jeppesen 2012

5 mg

Human

human

subcutaneous

single injection

Trial in people without random groups · n = 72

Hartmann 2012

20 mg

Human

human

subcutaneous

single injection

Trial in people without random groups · n = 72

Hartmann 2012

0.025 mg/kg once daily

Human

human

Not reported

24 weeks

Trial in people without random groups

Kocoshis 2020

0.05 mg/kg once daily

Human

human

Not reported

24 weeks

Trial in people without random groups

Kocoshis 2020

10 mg single dose

Human

human

subcutaneous

Not reported

Trial in people without random groups

Nave 2013

0.05 mg/kg/day

Human

human

subcutaneous

up to 24 months (NT/TED and PBO/TED) or up to 30 months (TED/TED)

Trial in people without random groups · n = 88

Schwartz 2016

0.025 mg/kg or 0.05 mg/kg once daily (teduglutide groups)

Human

human

Not reported

24 weeks

Trial in people without random groups · n = 59

Kocoshis 2020

0.05 or 0.10 mg/kg/d

Human

human

Not reported

52 weeks

Trial in people without random groups · n = 52

O'Keefe 2013

0.05 mg/kg/day

Human

human

Not reported

24 and 36 months

Trial in people without random groups · n = 50

Armstrong 2020

0.05 mg/kg/day

Human

human

Not reported

Trial in people without random groups · n = 18

Nakamura 2023

0.05 mg/kg/day

Human

human

Not reported

Trial in people without random groups · n = 14

Seidner 2018

0.05 mg/kg daily

Human

human

subcutaneous

7 days

Trial in people without random groups · n = 8

Iturrino 2016

0.05 mg/kg/day

Human

human

subcutaneous

Mean exposure 48.9 weeks

Trial in people without random groups · n = 3

Masumoto 2026

0.025 mg/kg/d

Human

human

Not reported

12 weeks

Trial in people without random groups

Carter 2017

0.05 mg/kg/d

Human

human

Not reported

12 weeks

Trial in people without random groups

Carter 2017

0.0125 mg/kg/d

Human

human

Not reported

12 weeks

Trial in people without random groups

Carter 2017

0.05 mg/kg/d

Human

human

Not reported

52 weeks

Trial in people without random groups

O'Keefe 2013

0.10 mg/kg/d

Human

human

Not reported

52 weeks

Trial in people without random groups

O'Keefe 2013

0.10 mg/kg/d

Human

human

subcutaneous

Not reported

Trial in people without random groups

Buchman 2010

10, 15, 20, 25, 30, 50, and 80 mg

Human

human

subcutaneous

8 days

Trial in people without random groups

Marier 2008

20 mg

Human

human

subcutaneous

8 days

Trial in people without random groups

Marier 2008

0.10 mg/kg/d

Human

human

Not reported

24 weeks

Trial in people without random groups

Tappenden 2013

0.05 mg/kg/d

Human

human

Not reported

24 weeks

Trial in people without random groups

Tappenden 2013

0.05 or 0.10 mg/kg/day

Human

human

Not reported

24 weeks

Trial in people without random groups

Seidner 2015

0.05 mg/kg/d

Human

human

Not reported

Median 89 weeks among patients achieving autonomy

Observational study · n = 134

Iyer 2017

0.05 mg/kg/dose

Animal

pig

Not reported

Study in live animals · n = 16

Pauline 2021

0.2 mg · kg · day

Animal

pig

Not reported

7 days

Study in live animals · n = 15

Thymann 2014

Context

Route

Amount

How often

How long

Agreement

Sources

Selected US GATTEX standard regimen for adults and pediatric patients 1 year of age and older with short bowel syndrome and parenteral-support dependence. This selection excludes eGFR below 60 mL/min/1.73 m2. The 5 mg kit is not recommended for pediatric patients below 10 kg.Official label dosing of an approved product

subcutaneous injectionThe label excludes intravenous and intramuscular administration. Injection sites alternate between thighs, upper arms, and abdomen.

0.05 mg/kg per dose

once daily

Not stated

Single official US label source.

Teduglutide

Teduglutide at a glance

What is teduglutide?

The history of teduglutide

Teduglutide structure and chemistry

What teduglutide studies show

Survival and serious illness

Stomach and gut

Daily life and fitness

Overall treatment results

Heart and blood vessels

Liver

Key teduglutide studies

Teduglutide clinical trials

Is teduglutide approved?

Teduglutide side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about teduglutide

Related peptides

Sources

Teduglutide

Teduglutide at a glance

What is teduglutide?

The history of teduglutide

Teduglutide structure and chemistry

What teduglutide studies show

Survival and serious illness

Stomach and gut

Daily life and fitness

Overall treatment results

Heart and blood vessels

Liver

Key teduglutide studies

Teduglutide clinical trials

Is teduglutide approved?

Teduglutide side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about teduglutide

Related peptides

Sources